Parkinsons Disease Methods and Protocols 1st Editon 2011 Softbound at Meripustak

Parkinsons Disease Methods and Protocols 1st Editon 2011 Softbound

Books from same Author: M. Maral Mouradian

Books from same Publisher: Humana Press

Related Category: Author List / Publisher List


  • Retail Price: ₹ 16235/- [ 5.00% off ]

    Seller Price: ₹ 15423

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 5.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 5.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)M. Maral Mouradian
    PublisherHumana Press
    Edition1st Edition
    ISBN9781617371752
    Pages317
    BindingSoftbound
    LanguageEnglish
    Publish YearAugust 2011

    Description

    Humana Press Parkinsons Disease Methods and Protocols 1st Editon 2011 Softbound by M. Maral Mouradian

    Parkinson’s disease is a progressive neurodegenerative disorder charact- ized clinically by tremor, rigidity, slow movements, and postural instability. Pathologically, dopaminergic neurons of the substantia nigra bear the brunt of the degeneration, though other neuronal groups can be affected as well. Although Parkinson’s disease is the only neurodegenerative disorder for which effective therapies are available, these treatment options are only symptomatic, do not influence the underlying degenerative process, and are associated with a high incidence of complications, particularly with their long-term use. The progressive nature of the disease and the limitations of its palliative therapies result in significant functional impairment. The chronic disability and the increased prevalence of the disease with the prolongation of life expectancy in developed countries make the social and economic impact of this disease quite high. For- nately, systematic basic and clinical research in this disease has yielded major new advances that render patients’ hopes for a cure considerably closer to reality. The application of molecular biologic methodologies in the study of Parkinson’s disease has begun to have a major impact only in recent years. Con- quently, the utility of these technologies is largely in the research arena, although their clinical applications are now being realized. Genetics.- Point Mutations in the ?-Synuclein Gene.- Autosomal Recessive Juvenile Parkinsonism (AR-JP): Genetic Diagnosis.- Molecular Pathogenetic Studies.- Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as ?-Synucleinopathies.- ?-Synuclein/Amyloid Interactions.- Functional Defect Conferred by the Parkinson's Disease-Causing ?-Synuclein (Ala30Pro) Mutation.- Molecular Biology of Dopamine-Induced Apoptosis.- Animal Models of Induced Apoptotic Death in the Substantia Nigra.- Apoptotic Morphology in Phenotypically Defined Dopaminergic Neurons of the Substantia Nigra.- The Role of Nitric Oxide in Parkinson's Disease.- Oxidative Stress Indices in Parkinson's Disease.- Molecular Aspects of Basal Ganglia Function.- Quantification of Tyrosine Hydroxylase mRNA.- Immunochemical Analysis of Dopamine Transporters in Parkinson's Disease.- Dopamine Transporter and Vesicular Monoamine Transporter Knockout Mice.- Transcription Mechanisms for Dopamine Receptor Genes.- Detection of DNA/Protein Interactions in Dopamine Receptor Genes.- In Situ Hybridization on Brain Tissue.- Regulation of Striatal N-Methyl-D-Aspartate Receptor (NMDAR) Function by Phosphorylation of its Subunits in Parkinsonian Rats.- Molecular Therapies.- Chronic Intracerebral Delivery of Trophic Factors via a Programmable Pump as a Treatment for Parkinsonism.- Grafting Genetically Engineered Cells into the Striatum of Nonhuman Primates.- Encapsulated Cell Implants as a Novel Treatment for Parkinson's Disease.- Neural Stem Cell Technology as a Novel Treatment for Parkinson's Disease.